Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pivanex · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Pivanex | DRUG | - |
| Docetaxel | DRUG | - |
Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); Treatment with one prior platinum-based chemotherapy regimen (Eligible patients may include: 1. Patients previously treated with adjuvant or neoadjuvant chemotherapy (must be completed within 6 mo...
Pivanex is an investigational small molecule being studied for the treatment of carcinoma, non-small-cell lung cancer. It is in Phase 2 clinical development and has not been approved by the FDA. One completed Phase 2 trial evaluated Pivanex in combination with docetaxel versus docetaxel monotherapy in patients with advanced non-small-cell lung cancer.
Pivanex is being developed by Titan Pharmaceuticals, Inc., a company traded on the Nasdaq under the ticker TTNP. The drug is an investigational small molecule in Phase 2 clinical development for non-small-cell lung cancer. Titan Pharmaceuticals has conducted one completed Phase 2 trial of Pivanex.
Pivanex is in Phase 2 clinical development. It is an investigational small molecule for non-small-cell lung cancer and has not been approved by the FDA. One Phase 2 trial has been completed, and there are no active trials currently listed for Pivanex.
Pivanex has been studied in one completed Phase 2 clinical trial, identified as NCT00073385. This trial was a comparative study of Pivanex plus docetaxel versus docetaxel monotherapy in patients with advanced non-small-cell lung cancer. The trial enrolled 225 participants across the United States, India, and the United Kingdom.
Pivanex is not FDA approved. It is an investigational small molecule in Phase 2 clinical development for non-small-cell lung cancer. The drug has completed one Phase 2 trial, but it remains under investigation and has not received regulatory approval.